Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV.

Enkosi Mondleki Clifford George Banda Nomathemba C Chandiwana Simiso Mandisa Sokhela Lubbe Wiesner Willem Daniel Francois Venter Gary Maartens Phumla Z Sinxadi

Published in: Southern African journal of HIV medicine (2022)

Dolutegravir exposure was marginally lower in participants with obesity, but this is not clinically significant. Our findings suggest that there is no need to dose adjust dolutegravir in people with obesity.

Keyphrases

insulin resistance
metabolic syndrome
weight loss
high fat diet induced
type diabetes
weight gain
antiretroviral therapy
hiv infected patients
adipose tissue
body mass index
physical activity